WHO ICTRP trial
A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults…
JPRN-jRCT2011250002 · Japan Primary Registries Network (JPRN) · Recruiting
Key facts
| Trial ID | JPRN-jRCT2011250002 |
|---|---|
| Public title | A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease |
| Scientific title | An Open Label Study to Investigate the Long-term Safety and Efficacy of Belimumab Administered Subcutaneously in Adults With Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD) |
| Primary sponsor | Ishibashi Hideyasu |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | 3 |
| Countries | Argentina;Japan;Australia;Japan;Belgium;Japan;Brazil;Japan;China;Japan;Denmark;Japan;Finland;Japan;France;Japan;Germany;Japan;Greece;Japan;Israel;Japan;Italy;Japan;South… |
| Conditions | systemic sclerosis associated interstitial lung disease (SSc-ILD). |
| Interventions | Belimumab is subqutaneously administered once a week for about maximun 5 years. |
| Registration date | Apr 28, 2025 |
| Target size | 5 |
| Secondary IDs | NCT06716606 |
| Registry page | jrct.mhlw.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: